down arrow

Ginkgo Bioworks Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US37611X1000
USD
7.97
-0.53 (-6.24%)

Aug 07

NYS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Azenta, Inc.
The Ensign Group, Inc.
Amedisys, Inc.
Agilon Health, Inc.
Encompass Health Corp.
Option Care Health, Inc.
Teladoc Health, Inc.
Guardant Health, Inc.
Acadia Healthcare Co., Inc.
Ginkgo Bioworks Holdings, Inc.
DaVita, Inc.

Why is Ginkgo Bioworks Holdings, Inc. ?

1
Poor long term growth as Operating profit has grown by an annual rate -274.96% of over the last 5 years
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -7.48%, its profits have risen by 44.7%
3
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 14.11% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -7.48% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ginkgo Bioworks Holdings, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Ginkgo Bioworks Holdings, Inc.
-40.79%
-0.49
105.05%
S&P 500
22.36%
0.70
20.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-9.33%
EBIT Growth (5y)
-204.67%
EBIT to Interest (avg)
-826.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.51%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.72
EV to EBIT
0.14
EV to EBITDA
0.17
EV to Capital Employed
-0.42
EV to Sales
-0.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-61.77%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -166.23 MM

NET PROFIT(HY)

Higher at USD -151.61 MM

-16What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at 6.85 %

RAW MATERIAL COST(Y)

Grown by 64.93% (YoY

NET SALES(Q)

Lowest at USD 19.47 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -300.79 %

Here's what is working for Ginkgo Bioworks Holdings, Inc.

Operating Cash Flow
Highest at USD -166.23 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit
Higher at USD -151.61 MM
than preceding 12 month period ended Mar 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Here's what is not working for Ginkgo Bioworks Holdings, Inc.

Net Sales
At USD 19.47 MM has Fallen at -54.22%
over average net sales of the previous four periods of USD 42.54 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Debt-Equity Ratio
Highest at 6.85 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales
Lowest at USD 19.47 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

Operating Profit Margin
Lowest at -300.79 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Raw Material Cost
Grown by 64.93% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."